TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00543543

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: GARDASIL
Description: GARDASIL (quadrivalent HPV \[Types 6, 11, 16, and 18\] L1 virus-like particle vaccine), 0.5 mL injection in 3 dose regimen

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Experimental: V503
Description: V503 (9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine), 0.5 mL injection in 3 dose regimen (and a fourth injection for Cohort 1 only).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: V503
Description: V503 (9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine), 0.5 mL injection in 3 dose regimen (and a fourth injection for Cohort 1 only).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: V503
Description: V503 (9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine), 0.5 mL injection in 3 dose regimen (and a fourth injection for Cohort 1 only).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: V503
Description: V503 (9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine), 0.5 mL injection in 3 dose regimen (and a fourth injection for Cohort 1 only).
Study: NCT03325270

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: labeled ferrous fumarate
Description: labeled iron as Ferrous Fumarate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: labeled ferrous fumarate + prebiotics
Description: labeled iron as Ferrous Fumarate + galacto-oligosaccharides

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: labeled ferrous sulfate + prebiotics
Description: labeled iron as Ferrous Sulfate + galacto-oligosaccharides
Study: NCT03813043

Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam injection
Description: Midazolam 2mg iv to be used as starting dose using Biased coins up and down method (BCM)
Study: NCT01046162

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam
Description: Single tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam
Description: Single tablet
Study: NCT00033605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: octreotide acetate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation
Study: NCT02530463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT00309478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 600mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate 40mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil implant
Description: Fluorouracil 600mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Zoladex 3.6mg/28 days for 3 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Nolvadex 20mg/day for 5 years
Study: NCT01033188

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single bundle
Description: Procedure:~Transarthroscopic technique with medial portal placement of the femoral tunnel. Harvest of the semitendinosus/gracilis (ST/G) tendons through a 3-5 cm incision at the pes anserinus. The femoral tunnel is positioned at the anatomic foot print determined by the anatomic landmarks. The graft will be fixed with an Endobutton CL on the femur and with an Biosure PK screw in the tibia with the knee close to extension. Prior to the final fixation, the knee will be taken through flexion and extension movements.The surgery will be carried out by an experienced knee surgeon.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double bundle
Description: Procedure:~Transarthroscopic technique. Harvest of the semitendinosus/gracilis (ST/G) tendons through a 3-5 cm incision at the pes anserinus.Through a medial portal 2 tunnels will be anatomically placed in the foot print on the femur and the two tibial tunnels will be placed using the Smith \& Nephew drill guide. The graft will be fixed with 2 Endobuttons on the femur and with 2 Biosure PK screws in the tibia. Prior to the final fixation, the knee will be taken through 20 flexion and extension movements. The PL bundle will be fixed with the knee close to ful extension. The surgery will be carried out by an experienced knee surgeon.
Study: NCT01527175

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Approach for ultrasound-guided subclavian venous catheterization
Description: Each SCV catheterization was performed under ultrasound-guidance with supraclvicular or infraclavicular approach.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Approach for ultrasound-guided subclavian venous catheterization
Description: Each SCV catheterization was performed under ultrasound-guidance with supraclvicular or infraclavicular approach.
Study: NCT04489459

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colistin
Description: Intravenous colistin 9 MIU IV infusion over 2 hours loading dose followed by maintenance dose 4.5 MIU IV infusion over 2 hours q12 h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colistin
Description: Intravenous colistin 9 MIU IV infusion over 2 hours loading dose followed by maintenance dose 4.5 MIU IV infusion over 2 hours q12 h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Intravenous meropenem 2 g IV infusion over 30 minutes q8 h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tigecycline
Description: Intravenous Tigecycline 100 mg IV infusion over 1 hour loading dose followed by maintenance dose 50 mg IV infusion over 1 hour q12
Study: NCT03250871

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: Hypnosis will be supervised by a nurse trained by the French Institute of Hypnosis.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo consists in non-hypnotic relaxation suggestions and in hearing white noise through headphones
Study: NCT02550041

Intervention type: OTHER
Group type: OTHER
Intervention: T specific response for diagnostic of aspergillus bronchitis
Study: NCT04118842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: Patients will receive a single dose on Study Day 1 and Study Day 20. Savolitinib will be administrated after a high fat, high calorie breakfast to reduce the risk of adverse events.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Patients will receive Rifampicin once daily on Study Day 15, 16, 17, 18, 19, 20 and 21. Rifampicin will be administered 1 hour before breakfast.
Study: NCT04436731

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxia Exposure
Description: Systemic oxygen levels will be titrated to attain hypoxemia as assessed by pulse oximetry.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Phenylephrine (0.0625 mcg/dL/min) will be locally infused via brachial artery catheter during the final 3 min of normoxia and hypoxia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine (12.5 ng/dL/min) will be locally infused via brachial artery catheter during the final 3 min of normoxia and hypoxia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentolamine
Description: Phentolamine will be locally infused via brachial artery catheter for 10 min before baseline measurement (12 mcg/dL/min) and the infusion will continue at a maintenance rate (5 mcg/dL/min) during acute normoxia and hypoxia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Regional forearm infusion at 8 ng/dL/min via brachial artery catheter during normoxia and hypoxia exposures
Study: NCT03005418

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Acellular Vessel (HAV)
Description: The investigational medicinal product (IMP) - the Human Acellular Vessel (HAV) is a sterile acellular tubular graft composed of human collagen types I and III and other extracellular matrix proteins, including fibronectin and vitronectin which can be used for arterial bypass or reconstruction in patients with life or limb threatening vascular trauma. The vessel is 6 mm in diameter and approximately 42 cm in length. The product is supplied on a silicone mandrel immersed in sterile phosphate buffered saline in a sealed and labeled plastic container. The Humacyte HAV is implanted using standard vascular surgical techniques similar to placement of predicate peripheral vascular prostheses.
Study: NCT01739361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02398838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Home administration of 200 mg mifepristone
Description: Home administration of 200 mg mifepristone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Home or clinic administration of 400 mcg buccal misoprostol
Description: Home or clinic administration of 400 mcg buccal misoprostol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Home or clinic administration of 400 mcg buccal misoprostol
Description: Home or clinic administration of 400 mcg buccal misoprostol
Study: NCT03342079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local Anesthetics,Topical
Description: topical anesthetic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local Anesthetics,Topical
Description: topical anesthetic
Study: NCT04488939

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane® Skinboosters™ Vital (SBV)
Description: Hyaluronic acid
Study: NCT03342079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: placebo topical anesthetic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: placebo topical anesthetic
Study: NCT00932919

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thought field therapy
Description: 5 sessions with Thought field therapy
Study: NCT02502175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: opium
Description: Opium tincture (10mg/ml), manufactured by Daroupakhsh.co, Tehran, Iran.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methadone
Description: Methadone (5mg/ml), manufactured by Daroupakhsh.co, Tehran, Iran.
Study: NCT02002832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone tablets
Description: Lurasidone tablets (40or80mg/day) and Risperidone tablets(Placebo)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone tablets
Description: Risperidone tablets(2-6mg/day) and Lurasidone tablets(Placebo)
Study: NCT01356940

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: identical placebo tablet administered bid for four weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: identical placebo tablet administered bid for four weeks
Study: NCT00932919

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive therapy
Description: 12 sessions of Cognitive therapy
Study: NCT02926846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous vancomycin & gentamicin with adjunctive lavage
Description: Intravenous vancomycin and gentamicin are administered, together with adjunctive lavage performed by automated peritoneal dialysis machine over 48 to 72 hours.~(choice of antibiotic is adjusted in accordance with the microbiology report when available)
Study: NCT00932919

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait list
Description: 3 months waiting, then randomized to either thought field therapy or cognitive therapy
Study: NCT05475470

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: finger-blade technique
Description: laparoscopic access technique for group a

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hasson's technique
Description: laparoscopic access technique for group b

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: veress needle technique
Description: laparoscopic access technique for group c
Study: NCT04473261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idoine Complex
Description: Iodine Complex spray form 2 puffs will be given three times a day
Study: NCT03234868

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Impression procedure
Description: Each patient will go through both type of impression during single appointment: first the digital impression and then the conventional one (to avoid residual impression materials for the optical impressions). The time necessary for each procedure will be recorded.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Impression procedure
Description: Each patient will go through both type of impression during single appointment: first the digital impression and then the conventional one (to avoid residual impression materials for the optical impressions). The time necessary for each procedure will be recorded.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Crown manufacturing procedures
Description: Test and control implant crowns will be screw-retained on a multi-unit abutment. The conventional crown will be made of a Zirconia framework veneered with cosmetic ceramics directly screwed on the multi-unit platform (no titanium base). The experimental crown will be made in full zirconia and designed in the TRIOS software.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crown manufacturing procedures
Description: Test and control implant crowns will be screw-retained on a multi-unit abutment. The conventional crown will be made of a Zirconia framework veneered with cosmetic ceramics directly screwed on the multi-unit platform (no titanium base). The experimental crown will be made in full zirconia and designed in the TRIOS software.
Study: NCT01167595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEP uP Protocol
Description: Protocol documents (i.e. pre-printed order, algorithm for advancing feed, and algorithm for calculating rate of administering feed as per 24hour volume) and a slide presentation coupled with educational reminders (posters and bedside notices) and practice helps (tool to remind nurse to measure and report nutritional adequacy) will be made available to all nurses, in bedside manuals and/or on the local intranet.
Study: NCT03021304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: It is a clear to opalescent, colorless to pale yellow sterile solution for SC injection, supplied in a single-use, prefilled syringe containing 100 mg/mL mepolizumab with sodium phosphate, citric acid, sucrose EDTA and polysorbate 80 within a safety syringe.
Study: NCT03218956

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement: Protein intake
Description: Oral consumption of houly experimental meals. Includes 4 meals containing a mixture of free amino acids, carbohydrates from a flavored liquid, fat from corn oil and protein free cookies.~The last 4 meals will in addition contain labelled labelled 13C phenylalanine.
Study: NCT05798208

Intervention type: DIAGNOSTIC_TEST
Intervention: blood pressure measurement
Description: Taking blood pressure with automated arm sphygmomanometer and pressure higher than 140/90 was considered abnormal

Intervention type: DIAGNOSTIC_TEST
Intervention: blood pressure measurement
Description: Taking blood pressure with automated arm sphygmomanometer and pressure higher than 140/90 was considered abnormal
Study: NCT00672256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Abstinence
Description: Smokers were scanned after having quitting smoking for 24 hours, and scanned after smoking as usual.
Study: NCT00266097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Cohort (-1) = 50 mg daily Cohort 1 = 50mg daily Cohort 2= 75 mg daily Cohort 3 = 100mg daily Cohort 4 = 100mg daily Cohort 5 = 150mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Gemcitabine will be given at a dose of 100 mg/m2 for the first cohort and escalated to a fixed dose of 200 mg/m2 for the remaining 3 cohorts

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Oxaliplatin will be given at 30 mg/m2 weekly for the first two cohorts and then will be dose-escalated to 45 mg/m2 and 60 mg/m2 for the next 2 in cohorts

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 5040 cGy, every week, up to 6 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 5040 cGy, every week, up to 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given weekly at a starting dose of 100mg/m2 in the first 3 cohorts and dose escalated to 200 mg/m2 for the remaining 2 cohorts

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: The Part II dose of oxaliplatin will be determined by Part I of the study. The dose for Part II will be one dose level increase from the MTD determined in Part I.
Study: NCT02926846

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intraperitoneal vancomycin & gentamicin
Description: Intraperitoneal vancomycin and gentamicin are administered, with the usual continuous ambulatory peritoneal dialysis schedule maintained.~(choice of antibiotic is adjusted in accordance with the microbiology report when available)
Study: NCT01246518

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MOB015
Description: Arm 1; MOB015 once a day for 3 months. Arm 2; MOB015 once a day for 9 months.
Study: NCT01123291

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: follow-up coronary angiography
Description: follow-up coronary angiography at 8-12 months after discharge for percutaneous coronary intervention

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clinical follow-up
Description: no routine follow-up coronary angiography at 8-12 months after discharge for percutaneous coronary intervention
Study: NCT04378582

Intervention type: OTHER
Intervention: risk factors
Description: This is an observational study, so there are no interventions. Investigators will collect data about demographics, comorbidities, and other risk factors such as severity of disease at admission, need for advanced life support, need for invasive mechanical ventilation and ventilator parameters on day1 of mechanical ventilation or ICU admission as potentially association with survival

Intervention type: OTHER
Intervention: risk factors
Description: This is an observational study, so there are no interventions. Investigators will collect data about demographics, comorbidities, and other risk factors such as severity of disease at admission, need for advanced life support, need for invasive mechanical ventilation and ventilator parameters on day1 of mechanical ventilation or ICU admission as potentially association with survival
Study: NCT03962192

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attitudinal measures
Description: A collection of 3 distinct attitudinal instruments comprise this survey.
Study: NCT03422510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXA-10
Description: CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitro-oleic acid (OA-NO2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXA-10
Description: CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitro-oleic acid (OA-NO2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXA-10
Description: CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitro-oleic acid (OA-NO2)
Study: NCT00611325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Avastin was administered intravenously at the dose 15 mg/kg every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Avastin was administered intravenously at the dose 15 mg/kg every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib was administered on days 1, 4, 8, 11, 22, 25, 29, \& 32 of a 42-day cycle. Bortezomib was 1.7 mg/m2 for patients not taking EIAEDs \& 2.5 mg/m2 for patients taking EIAEDs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib was administered on days 1, 4, 8, 11, 22, 25, 29, \& 32 of a 42-day cycle. Bortezomib was 1.7 mg/m2 for patients not taking EIAEDs \& 2.5 mg/m2 for patients taking EIAEDs.
Study: NCT03422510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXA-10
Description: CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitro-oleic acid (OA-NO2)